Form 4: Greenwich LifeSciences VP of Clinical Regulatory Affairs Acquires Stock Options

Jaye Thompson, VP of Clinical Regulatory Affairs at Greenwich LifeSciences, acquired 149,818 stock options on December 24, 2024.

Summary

• Jaye Thompson, the VP of Clinical Regulatory Affairs at Greenwich LifeSciences, has acquired 149,818 stock options.
• These options were granted on December 24, 2024, with an exercise price of $12.16.
• The options vest over time, with 37,455 vesting immediately and the remainder vesting monthly over 36 months.
• The vesting schedule is also dependent on the reporting person's employment tenure, with 10% vesting after 1-2 years, 20% after 2-3 years, 30% after 3-4 years, and the remainder after 4 years of employment.
• Following this transaction, Thompson now beneficially owns 299,636 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns executive interests with company performance. There are no negative implications.

Positives

• The grant of stock options to a key executive like the VP of Clinical Regulatory Affairs can be seen as a positive incentive for performance and retention.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

This is a standard practice for incentivizing key personnel in publicly traded companies, particularly in the biotech sector where long-term commitment is crucial for drug development and regulatory approvals.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in the biotechnology industry.
• Vesting schedules tied to both time and performance are also standard practice to align executive interests with long-term company success.
• Companies like Amgen, Gilead, and Regeneron also use similar stock option plans for their executives.

Stakeholder Impact

• The stock option grant could be viewed positively by shareholders as it incentivizes a key executive.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, insider trading, executive compensation, Greenwich LifeSciences, GLSI, Jaye Thompson, vesting, clinical regulatory affairs